The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Taking the patient off osimertinib is indicated (PMID 31882494) plus corticosteroid therapy.

Publications

Lin Z, Wu L, Yu Y, Jiang J, Yang Y, Xiao G

Case Report: Osimertinib-induced acute interstitial lung disease.

Frontiers in pharmacology 2025;16 — 2025 — 1608733

Possick JD

Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis.

Chest 2022 Nov;162;965-967 — 2022 Nov — 965-967

Le Guen Y, Lederlin M, Triquet L, Lesouhaitier M, Le Tulzo Y, Ricordel C

[Pulmonary manifestations induced by osimertinib].

Revue des maladies respiratoires 2021 Dec 27;; — 2021 Dec 27

Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Investigational new drugs 2021 04;39;571-577 — 2021 04 — 571-577

Lu H, Dowell J

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

In vivo (Athens, Greece) 2020 Jan-Feb;34;315-319 — 2020 Jan-Feb — 315-319

Fan M, Mo T, Shen L, Yang L

Osimertinib-induced severe interstitial lung disease: A case report.

Thoracic cancer 2019 Jul;10;1657-1660 — 2019 Jul — 1657-1660

Deng SM, Huang JA, Chen YB

Fatal interstitial lung disease associated with AZD9291.

Journal of cancer research and therapeutics 2018 Dec;14;S1227-S1229 — 2018 Dec — S1227-S1229

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Apr 20;35;1288-1296 — 2017 Apr 20 — 1288-1296